losartan has been researched along with Obesity in 44 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 9.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 9.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, in which hypertensive patients with ECG LV hypertrophy (Cornell voltage-duration product, > 2440 mm x ms and/or SV1 + RV(5-6) > 38 mm) were randomized to > or = 4 years double-blinded treatment with losartan or atenolol." | 9.09 | Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2000) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 9.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| "To evaluate the follicular development of female Wistar rats with obesity induced by the cafeteria diet, submitted to the administration of losartan (LOS), an antagonist of the AT1 receptor of Angiotensin II." | 7.81 | [Blockade of AT1 receptor of Angiotensin II reduces the number of antral follicles in female rats with obesity induced by cafeteria diet]. ( Balbo, SL; Franci, CR; Gobo, CG; Menegotto, JB; Paz, ED; Sagae, SC; Yamashita, PK, 2015) |
| " ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study." | 7.70 | Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. ( Dahlöf, B; Devereux, RB; Jern, S; Kjeldsen, SE; Okin, PM, 2000) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 5.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| "8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.17 | Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lund, BP; Nieminen, MS; Okin, PM; Wachtell, K, 2013) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 5.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, in which hypertensive patients with ECG LV hypertrophy (Cornell voltage-duration product, > 2440 mm x ms and/or SV1 + RV(5-6) > 38 mm) were randomized to > or = 4 years double-blinded treatment with losartan or atenolol." | 5.09 | Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2000) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 5.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| "It has been described that the cardiac dysfunction in the obesity model is because of collagen imbalance and that angiotensin II (Ang II) contributes to myocardial fibrosis." | 3.96 | Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats. ( Cicogna, AC; Corrêa, CR; da Silva-Bertani, DCT; de Oliveira, EM; de Souza, SLB; de Tomasi, LC; Fernandes, T; Freire, PP; Mota, GAF; Padovani, CR; Sant'Ana, PG; Vileigas, DF, 2020) |
| "The high-fat diet elicited overweight, insulin resistance and adipocyte hypertrophy in the high-fat group, all of which losartan rescued in the high-fat-losartan group." | 3.85 | AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice. ( Barbosa-da-Silva, S; de Oliveira Santos, F; Graus-Nunes, F; Rachid, TL; Souza-Mello, V, 2017) |
| "Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 weeks." | 3.85 | Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. ( Bedossa, P; Cammue, B; Cassiman, D; Nevens, F; Spincemaille, P; Thevissen, K; Van den Berghe, G; van der Merwe, S; van Pelt, J; Vander Elst, I; Vanhorebeek, I; Verbeek, J; Windmolders, P, 2017) |
| "To evaluate the follicular development of female Wistar rats with obesity induced by the cafeteria diet, submitted to the administration of losartan (LOS), an antagonist of the AT1 receptor of Angiotensin II." | 3.81 | [Blockade of AT1 receptor of Angiotensin II reduces the number of antral follicles in female rats with obesity induced by cafeteria diet]. ( Balbo, SL; Franci, CR; Gobo, CG; Menegotto, JB; Paz, ED; Sagae, SC; Yamashita, PK, 2015) |
| "Glucose metabolism, insulin, lipid, and ACE activity disorders observed with obesity were minimized by Losartan." | 3.80 | AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. ( Campos, DH; Cicogna, AC; Fernandes, T; Guizoni, DM; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, EM; Oliveira-Junior, SA; Padovani, CR, 2014) |
| " Blocking the actions of Angiotensin II with an AT1 receptor antagonist (Losartan), has beneficial effects in patients with insulin resistance or type 2 diabetes mellitus." | 3.77 | ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. ( Friedrich, SO; Huisamen, B; Lochner, A; Pêrel, SJ; Salie, R; Strijdom, H, 2011) |
| " ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study." | 3.70 | Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. ( Dahlöf, B; Devereux, RB; Jern, S; Kjeldsen, SE; Okin, PM, 2000) |
| "Patients with the metabolic syndrome have three or more of five cardiovascular risk factors and increased oxidative stress, arterial stiffness and pressor responses to exercise, which may contribute to their threefold greater risk for coronary heart disease." | 2.71 | Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. ( Egan, BM; Jesri, A; Morrow, JD; Nashar, K; Nguyen, JP, 2004) |
| "Obesity has been shown to be associated with increased left ventricular mass (LVM) and heart sympathetic activity even in nonhypertensive subjects." | 2.71 | Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. ( Amador, N; Encarnación, JJ; Guízar, JM; López, M; Rodríguez, L, 2005) |
| "We studied the effect of apelin treatment on obesity-induced type 2 diabetes mellitus (T2DM) and possible interaction between apelin/APJ system and renin-angiotensin system (RAS)." | 1.51 | Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. ( Ahmed, MM; Kamar, SS; Mahmoud, MM; Rashed, L; Sabry, MM; Shoukry, HS, 2019) |
| "Treatment with losartan reduced urinary protein excretion and blood lipids (triglyceride and cholesterol) dose-dependently in both studies." | 1.48 | Losartan improves renal function and pathology in obese ZSF-1 rats. ( Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018) |
| "Losartan treatment also abrogated fibro-inflammatory disease, assessed by markers at the protein and messenger level." | 1.39 | Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. ( Declèves, AE; Rychak, JJ; Sharma, K; Smith, DJ, 2013) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Metabolic syndrome has emerged as the major cause of atherosclerosis." | 1.33 | Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. ( Huang, KT; Natarajan, R; Rodríguez-Iturbe, B; Shahkarami, A; Vaziri, ND; Xu, ZG, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.82) | 18.2507 |
| 2000's | 16 (36.36) | 29.6817 |
| 2010's | 21 (47.73) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| do Carmo, JM | 1 |
| Dai, X | 1 |
| Aitken, N | 1 |
| Larson, KM | 1 |
| Omoto, ACM | 1 |
| Gulke, RR | 1 |
| Wang, Z | 1 |
| Li, X | 1 |
| Mouton, AJ | 1 |
| Hall, JE | 2 |
| da Silva, AA | 1 |
| Ardiana, M | 1 |
| Suryawan, IGR | 1 |
| Hermawan, HO | 1 |
| Harsoyo, PM | 1 |
| Sufiyah, IM | 1 |
| Muhammad, AR | 1 |
| Zaini, BSI | 1 |
| da Silva-Bertani, DCT | 1 |
| Vileigas, DF | 1 |
| Mota, GAF | 1 |
| de Souza, SLB | 1 |
| Sant'Ana, PG | 1 |
| Freire, PP | 1 |
| de Tomasi, LC | 1 |
| Corrêa, CR | 1 |
| Padovani, CR | 2 |
| Fernandes, T | 2 |
| de Oliveira, EM | 1 |
| Cicogna, AC | 2 |
| Fu, Z | 1 |
| Wang, F | 1 |
| Liu, X | 1 |
| Hu, J | 1 |
| Su, J | 1 |
| Lu, X | 1 |
| Lu, A | 1 |
| Cho, JM | 1 |
| Symons, JD | 1 |
| Zou, CJ | 1 |
| Yang, T | 1 |
| Su, Z | 1 |
| Widomski, D | 1 |
| Nikkel, A | 1 |
| Leys, L | 1 |
| Namovic, M | 1 |
| Donnelly-Roberts, D | 1 |
| Gopalakrishnan, M | 1 |
| McGaraughty, S | 1 |
| Sabry, MM | 1 |
| Mahmoud, MM | 1 |
| Shoukry, HS | 1 |
| Rashed, L | 1 |
| Kamar, SS | 1 |
| Ahmed, MM | 1 |
| Castoldi, G | 1 |
| di Gioia, CRT | 1 |
| Roma, F | 1 |
| Carletti, R | 1 |
| Manzoni, G | 1 |
| Stella, A | 1 |
| Zerbini, G | 1 |
| Perseghin, G | 1 |
| Sagae, SC | 2 |
| Lubaczeuski, C | 1 |
| Zacharias, P | 1 |
| Bonfleur, ML | 1 |
| Franci, CR | 2 |
| Sanvitto, GL | 1 |
| Nedogoda, SV | 1 |
| Ledyaeva, AA | 1 |
| Chumachok, EV | 1 |
| Tsoma, VV | 1 |
| Mazina, G | 1 |
| Salasyuk, AS | 1 |
| Barykina, IN | 1 |
| Declèves, AE | 1 |
| Rychak, JJ | 1 |
| Smith, DJ | 1 |
| Sharma, K | 1 |
| Oliveira-Junior, SA | 1 |
| Martinez, PF | 1 |
| Guizoni, DM | 1 |
| Campos, DH | 1 |
| Oliveira, EM | 1 |
| Okoshi, MP | 1 |
| Okoshi, K | 1 |
| Vatseba, MO | 1 |
| Gobo, CG | 1 |
| Paz, ED | 1 |
| Menegotto, JB | 1 |
| Yamashita, PK | 1 |
| Balbo, SL | 1 |
| Kho, MC | 1 |
| Lee, YJ | 1 |
| Park, JH | 1 |
| Kim, HY | 1 |
| Yoon, JJ | 1 |
| Ahn, YM | 1 |
| Tan, R | 1 |
| Park, MC | 1 |
| Cha, JD | 1 |
| Choi, KM | 1 |
| Kang, DG | 1 |
| Lee, HS | 1 |
| Graus-Nunes, F | 1 |
| Rachid, TL | 1 |
| de Oliveira Santos, F | 1 |
| Barbosa-da-Silva, S | 1 |
| Souza-Mello, V | 1 |
| Verbeek, J | 1 |
| Spincemaille, P | 1 |
| Vanhorebeek, I | 1 |
| Van den Berghe, G | 1 |
| Vander Elst, I | 1 |
| Windmolders, P | 1 |
| van Pelt, J | 1 |
| van der Merwe, S | 1 |
| Bedossa, P | 1 |
| Nevens, F | 1 |
| Cammue, B | 1 |
| Thevissen, K | 1 |
| Cassiman, D | 1 |
| Huisamen, B | 1 |
| Pêrel, SJ | 1 |
| Friedrich, SO | 1 |
| Salie, R | 1 |
| Strijdom, H | 1 |
| Lochner, A | 1 |
| Huber, DA | 1 |
| Schreihofer, AM | 1 |
| Fogari, R | 2 |
| Mugellini, A | 2 |
| Circelli, M | 1 |
| Cremonesi, G | 1 |
| Gerdts, E | 2 |
| de Simone, G | 2 |
| Lund, BP | 1 |
| Okin, PM | 3 |
| Wachtell, K | 3 |
| Boman, K | 2 |
| Nieminen, MS | 3 |
| Dahlöf, B | 4 |
| Devereux, RB | 4 |
| Lteif, AA | 1 |
| Chisholm, RL | 1 |
| Gilbert, K | 1 |
| Considine, RV | 1 |
| Mather, KJ | 1 |
| Ram, CV | 1 |
| Ramaswamy, K | 1 |
| Qian, C | 1 |
| Biskupiak, J | 1 |
| Ryan, A | 1 |
| Quah, R | 1 |
| Russo, PA | 1 |
| Deji, N | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Tanaka, Y | 1 |
| Nishiyama, A | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Gupte, M | 1 |
| Thatcher, SE | 1 |
| Boustany-Kari, CM | 1 |
| Shoemaker, R | 1 |
| Yiannikouris, F | 1 |
| Zhang, X | 1 |
| Karounos, M | 1 |
| Cassis, LA | 2 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Nashar, K | 1 |
| Nguyen, JP | 1 |
| Jesri, A | 1 |
| Morrow, JD | 1 |
| Egan, BM | 1 |
| Amador, N | 1 |
| Encarnación, JJ | 1 |
| Guízar, JM | 1 |
| Rodríguez, L | 1 |
| López, M | 1 |
| Boustany, CM | 1 |
| Brown, DR | 1 |
| Randall, DC | 1 |
| Palmieri, V | 2 |
| Hille, DA | 1 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Julius, S | 2 |
| Kjeldsen, SE | 2 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Omvik, P | 1 |
| Oparil, S | 2 |
| Xu, ZG | 2 |
| Lanting, L | 1 |
| Vaziri, ND | 3 |
| Li, Z | 2 |
| Sepassi, L | 1 |
| Rodriguez-Iturbe, B | 3 |
| Natarajan, R | 2 |
| Quiroz, Y | 1 |
| Shahkarami, A | 2 |
| Huang, KT | 1 |
| Siddiqui, AH | 1 |
| Hussain, T | 1 |
| Chu, KY | 1 |
| Leung, PS | 1 |
| Kopp, UC | 1 |
| Cicha, MZ | 1 |
| Yorek, MA | 1 |
| Abate, N | 1 |
| Chen, E | 1 |
| Creager, MA | 1 |
| Galet, V | 1 |
| Jia, G | 1 |
| Lerman, A | 1 |
| Lyle, PA | 1 |
| Pool, J | 1 |
| Tershakovec, AM | 1 |
| Crary, GS | 1 |
| Swan, SK | 1 |
| O'Donnell, MP | 1 |
| Kasiske, BL | 1 |
| Katz, SA | 1 |
| Keane, WF | 1 |
| Alonso-Galicia, M | 1 |
| Brands, MW | 1 |
| Zappe, DH | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Preti, P | 1 |
| Corradi, L | 1 |
| Lusardi, P | 1 |
| Jern, S | 1 |
| Carlson, SH | 1 |
| Shelton, J | 1 |
| White, CR | 1 |
| Wyss, JM | 1 |
| Roman, MJ | 1 |
| Papademetriou, V | 1 |
| Bloomgarden, ZT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity: a Retrospective Study[NCT04481464] | 500 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| [NCT00005474] | 1,063 participants (Actual) | Observational | 1996-09-30 | Completed | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure[NCT00289887] | Phase 3 | 261 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Psychosocial Factors and Cardiovascular Disease[NCT00005315] | 0 participants | Observational | 1993-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.9 |
| Placebo | -7.1 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -14.1 |
| Placebo | -6.0 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -9.7 |
| Placebo | -6.9 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -16.7 |
| Placebo | -6.8 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -19.1 |
| Placebo | -6.4 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.1 |
| Placebo | -6.8 |
1 review available for losartan and Obesity
| Article | Year |
|---|---|
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
9 trials available for losartan and Obesity
34 other studies available for losartan and Obesity
| Article | Year |
|---|---|
Sex differences in weight gain, blood pressure control, and responses to melanocortin-4 receptor antagonism in offspring from lean and obese parents.
Topics: Adrenergic Agents; Adult; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Obesity; Rec | 2023 |
Perindopril and losartan attenuate pro-coagulation factors in human adipocytes exposed to SARS-CoV-2 spike protein.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Convertin | 2023 |
Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats.
Topics: Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type I; C | 2020 |
Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diet, High-Fat; Human Umbilical Vein En | 2021 |
Losartan improves renal function and pathology in obese ZSF-1 rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cholesterol; Diabetes Mellitus, Experi | 2018 |
Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apelin; Biomarkers; Blood Glucose; Diabetes Mellit | 2019 |
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Di | 2019 |
Prevention of metabolic disorders and reproductive performance deficits by the blockade of Angiotensin II AT1 receptor in female rats fed with cafeteria diet.
Topics: Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Body Weight; Cholesterol; Diet, High-Fat; | 2013 |
Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Diet, High-Fat; Disease Models, Animal | 2013 |
AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Glucose; Class Ia Phosphatidyl | 2014 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arterie | 2013 |
[Blockade of AT1 receptor of Angiotensin II reduces the number of antral follicles in female rats with obesity induced by cafeteria diet].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Diet; Energy Intake; Female; Food | 2015 |
Fermented Red Ginseng Potentiates Improvement of Metabolic Dysfunction in Metabolic Syndrome Rat Models.
Topics: Adipocytes; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Blood Pressur | 2016 |
AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice.
Topics: Adipocytes, Beige; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Gl | 2017 |
Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; CD36 Antigens; Collagen Type I, alpha 1 Chain; Dru | 2017 |
ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiac Output; Diet; In Vitro Techniques; Insulin | 2011 |
Altered regulation of the rostral ventrolateral medulla in hypertensive obese Zucker rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain Stem; Excita | 2011 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compou | 2011 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice.
Topics: 3T3-L1 Cells; Adipocytes; Adiposity; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor B | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Dietary Fats; Disease Susceptibili | 2005 |
Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arachidonic Acid; Enzymes | 2005 |
Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2005 |
Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemokine CCL2; Collagen; Extracellular Matrix; Fi | 2005 |
Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Bo | 2007 |
Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blotting, Western; Caspase 3; Diabetes | 2007 |
Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Baroreflex; Capsaicin; Diabetes Mell | 2008 |
The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1995 |
Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; | 1996 |
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Body Mass Index; Electrocardiography; Female; Humans; Hypertension; H | 2000 |
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; B | 2000 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |